Founded in 2011 by Truffle Capital, Affluent Medical is a French MedTech company specializing in innovative, next-generation minimally invasive implants to restore essential physiological functions for the treatment of heart disease, vascular disease and urinary incontinence.
Affluent Medical's four medical devices are currently in the pre-clinical or clinical phase:
- EPYGON, 1st physiological transcatheter mitral valve;
- KALIOS, 1st post-intervention fully adjustable medical device for mitral valve repair;
- ARTUS, 1st artificial sphincter that can be activated electronically to treat urinary incontinence;
- KARDIOZIS, 1st endovascular prosthesis technology avoiding endoleaks
Clinical-stage product portfolio are securing company's success and efficacy of implants is already proven by preclinical studies and first clinical series.
See website
Synoptical view
- Truffle investment
- € 28M
Management team
In summary
Affluent Medical is a French medical company specializing in innovative, next-generation, minimally invasive implants
To date, Affluent Medical has developed four medical devices in the preclinical or clinical phase:
-
EPYGON: The first transcatheter mitral valve to restore natural blood flow and save the ventricle. Currently, 4 million patients in Europe, the United States and Asia suffer from severe mitral valve regurgitation without access to optimal therapies.
-
KALIOS: The first fully adjustable mitral valve repair medical device designed to effectively meet the needs of mitral insufficiency patients, representing 1% of the world population.
-
ARTUS: The first electronically activatable artificial sphincter to treat urinary incontinence. 1 in 4 adults suffer from stress urinary incontinence, with a high prevalence among women.
-
4EVAR: The first endovascular prosthetic technology to prevent endoleaks and reduce aneurysm size in the abdominal aortic aneurysm that affects 5 to 10% of men between the ages of 65 and 80.
They talk about it
Affluent Medical has recently made significant progress and is now entering an intense phase of clinical trials. Our renewed management team, including key additional skills, will enable the Group to strengthen and secure the validation of these products for regulatory approval.
